Personalized multimodality therapy with immune checkpoint inhibitors (ICI), chemotherapy (CT), and targeted treatment (TT) in advanced refractory cancer.
Rattachement africain : us, it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
e14254 Background: Therapy for advanced refractory malignancies remains a major challenge. As the combination of ICI and CT has been shown in some cancers to be superior to CT alone, and as ICI, CT, and TT have efficacy, but divergent toxicity; this combination was chosen for treating patients with such diseases. Methods: Treatment was highly personalized and was designed based on diagnosis, prior therapy and eligibility for TT. ICI included pembrolizumab in 7 (2 in combination with ipilimumab), nivolumab in 10, and atezolizumab in 2. Chemotherapy was given in 28-day cycles. Multiagent CT cycles were given in 17, and single-agent in 2.13 received platinum and 10 taxanes. TT included erlotinib 4, cituxumab 2, bevacizumab 2, dabrafenib/trametinib 3, crizotinib 1, alectinib 1, sorafenib 1, everolimus 1. 4 were not eligible for TT. Results: From 04/2016 to 10/2018 19 consecutive patients (PT) were treated; median (M), age 62 (27-82), ECOG PS 2 (0-4), female 15/male 4. Tumor type; lung 8, pancreas 3, lymphoma 2, melanoma 2, cholangioCA 1, ureter 1, cervix 1, Glioblastoma Multiforme 1. 13 PT had prior therapy, M2(1-11). 7 had prior ICI, 3 prior TT. Disease was bulky in 6. Response was based on PET evaluation with tumor regression depicted after cycle #1. 11 achieved CR (57%), M 6+ months (1+-15+), 7 PR (37%), M 4 months (1+-7) and 1 SD 7 months. 3 intracranial metastases; 2 CR, 1 PR. Response was seen in extensive prior therapy, bulky disease, poor performance, and prior ICI. No unexpected side effects were observed. Grade 3-4 adverse events; 12.7%, primarily hematologic. Conclusions: The personalized combination of ICI, CT, and TT in advanced refractory diverse cancer diseases is associated with high clinical activity. Further evaluation in clinical trials is strongly indicated.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Personalized multimodality therapy with immune checkpoint inhibitors (ICI), chemotherapy (CT), and targeted treatment (TT) in advanced refractory cancer.
- Date Crossref
- 20/05/2019
- Éditeur
- American Society of Clinical Oncology (ASCO)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Salem Hospital pays non établi dans la noticeÉtablissement de santé
-
Christus Stehlin Foundation for Cancer Research pays non établi dans la noticeOrganisation à but non lucratif
-
Houston Medical Center pays non établi dans la noticeÉtablissement de santé
-
Baylor College of Medicine Department of Pathology pays non établi dans la noticeUniversité ou école supérieure
-
University of Palermo pays non établi dans la noticeUniversité ou école supérieure
-
Salem Onc Centre pays non établi dans la noticeInstitution
-
Jabboury Foundation for Cancer Research pays non établi dans la noticeOrganisation à but non lucratif
-
Houston Medical Imaging pays non établi dans la noticeInstitution
-
Università degli Studi di Palermo pays non établi dans la noticeInstitution
Salem Hospital, Christus Stehlin Foundation for Cancer Research et Houston Medical Center, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.